CD274 and non-small cell lung carcinoma: The phase III PACIFIC trial was the first pivotal study investigating the role of durvalumab, an anti-PD-L1 antibody, as consolidation treatment in locally advanced unresectable stage III NSCLC after concomitant chemoradiation therapy (CRT) [12].